Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
for
Recurrent Endometrial Carcinoma,
Location: 219 recruiting locations
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT05554328
Phase2, Recruiting
Active & Responsive
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
for
Cervical Cancer,
Location: 13 recruiting locations
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT04895709
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial
for
Endometrial Cancer
Location: 2 recruiting locations
Sponsor: University of Alberta
Sex: Female
Age: 18+
Code: NCT06038032
Recruiting
Active & Responsive
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
for
Cervical Cancer, Metastatic Cervical Cancer
Location: 3 recruiting locations
Sponsor: Georgetown University
Sex: Female
Age: 18+
Code: NCT04865887
Phase2, Recruiting
Active & Responsive
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer